Compare FGBI & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | EQ |
|---|---|---|
| Founded | 1934 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 140.1M |
| IPO Year | 2014 | 2018 |
| Metric | FGBI | EQ |
|---|---|---|
| Price | $8.71 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 14.0K | ★ 404.3K |
| Earning Date | 04-27-2026 | 05-25-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $0.76 |
| 52 Week High | $11.02 | $3.54 |
| Indicator | FGBI | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 37.91 |
| Support Level | $8.24 | $1.68 |
| Resistance Level | $8.86 | $1.97 |
| Average True Range (ATR) | 0.29 | 0.17 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 72.64 | 10.11 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana through several banking facilities. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and, to a lesser extent, consumer and multifamily loans. The company is engaged in a single line of business as a financial institution, which provides a full range of banking, financial, and trust services to state, county, and local government entities, individuals, and small and commercial businesses.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.